Cryotherapy for Cutaneous Kaposi's Sarcoma (KS) Associated with Acquired Immune Deficiency Syndrome (AIDS): A Phase II Trial

  title={Cryotherapy for Cutaneous Kaposi's Sarcoma (KS) Associated with Acquired Immune Deficiency Syndrome (AIDS): A Phase II Trial},
  author={Jordan Tappero and Timothy G. Berger and Lawrence D Kaplan and Paul A. Volberding and James O. Kahn},
  journal={JAIDS Journal of Acquired Immune Deficiency Syndromes},
Summary:To assess the response and toxicity of liquid nitrogen cryotherapy for cutaneous lesions of Kaposi's sarcoma (KS) associated with AIDS, we evaluated 20 subjects with biopsy-proven KS in a phase II clinical trial. Subjects had two to four cutaneous KS indicator lesions treated with liquid nitrogen cyrotherapy. Treatment was repeated at 3 week intervals, allowing adequate healing time. On average, subjects received three treatments per lesion with a mean follow-up time of 11 weeks (range… 

Evaluation of Effectiveness of Cryotherapy on the Treatment of Cutaneous Kaposi's Sarcoma

Liquid nitrogen cryotherapy is safe and cost‐efficient and can be readily adopted as an effective primary therapy for cutaneous KS lesions that respond slowly or show incomplete cosmetic improvement after systemic therapies.

Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials.

Alitretinoin gel has significant antitumor activity as a topical treatment for AIDS-related KS lesions, substantially reduces the incidence of disease progression in treated lesions, and is generally well tolerated.

Treatment of Kaposi’s Sarcoma

It is hoped that liposome-encapsulated cytotoxic chemotherapy and antiangiogenic therapies will prove more effective and less toxic than the treatment strategies currently in use.

AIDS-related Kaposi's sarcoma: current treatment options, future trends.

Clinical studies have shown alitretinoin gel (Panretin) to be a useful alternative or adjunct to other treatments for the management of cutaneous KS lesions and pathogenesis-directed therapies show promise for the effective control of this disease.

Kaposi's sarcoma: case report and treatment options.

A case of Kaposi's sarcoma is reported in a newly diagnosed retroviral homosexual patient with CD4 count of 21 who had multiple firm discrete violaceous plaques and nodules scattered over the face, scalp, hard palate, trunk and genitalia.

Caution in the use of local therapies for Kaposi's sarcoma.

Clinicians should be aware of additional safety precautions and potential side effects that should be conveyed to their patients before initiating therapy on the use of liquid nitrogen cryotherapy and intralesional vinblastine chemotherapy, according to recently completed efficacy trials.

Diagnosis and treatment of classic and iatrogenic Kaposi's sarcoma: Italian recommendations

Kaposi's sarcoma (KS) is a lymphangioproliferative disorder associated with Human herpesvirus 8 (HHV8) infection. Four clinical subtypes are recognized: classic, endemic, epidemic (HIV-related) and